--- title: "Tirzepatide: what sources report" url: https://humanpeptides.fyi/peptides/tirzepatide site: humanpeptides.fyi last_reviewed: 2026-10-11 --- # Tirzepatide > humanpeptides.fyi makes no claims of its own. Every statement below reports what a cited source says, with its link. Not medical advice. Tirzepatide: Once-weekly injectable dual GIP/GLP-1 receptor agonist. The sources cited here most often discuss it for: Major weight loss; Blood sugar and heart risk; Less sleep apnea. Evidence label: Approved (specific use). ## At a glance - **Type:** Peptide - **Family:** Weight & Metabolic - **Evidence label:** Approved (specific use) (5 of 5) - **Regulatory status:** Tirzepatide was first approved in the US in 2022, and Zepbound is FDA-approved, with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or with overweight and a weight-related condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity. - **Goals discussed:** Fat Loss & Metabolism, Heart, Liver & Kidney, Sleep - **Also called:** Mounjaro, Zepbound, LY3298176, twincretin, tirz, Tirz - **Last reviewed:** 2026-10-11 ## What is Tirzepatide? - Once-weekly injectable dual GIP/GLP-1 receptor agonist; FDA-approved as Mounjaro (type 2 diabetes; MACE reduction in high-CV-risk adults) and Zepbound (chronic weight management; moderate-severe obstructive sleep apnea with obesity) Sources: , **Regulatory status:** Tirzepatide was first approved in the US in 2022, and Zepbound is FDA-approved, with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or with overweight and a weight-related condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity. Source: ## What is Tirzepatide researched for? ### 1. Major weight loss - Weight loss: 20.9% mean at 72 weeks on 15 mg vs 3.1% placebo (SURMOUNT-1 phase 3 RCT) Sources: , - Goals: [Fat Loss & Metabolism](https://humanpeptides.fyi/objectives/fat-loss) ### 2. Blood sugar and heart risk - Glycemic control in type 2 diabetes and cardiovascular event reduction in high-risk adults (FDA label, SURPASS program) Sources: , - Goals: [Fat Loss & Metabolism](https://humanpeptides.fyi/objectives/fat-loss), [Heart, Liver & Kidney](https://humanpeptides.fyi/objectives/organs) ### 3. Less sleep apnea - Reduces obstructive sleep apnea severity (AHI -25 to -29 events/h vs ~-5 placebo, SURMOUNT-OSA RCT) - MASH resolution in 44-62% vs 10% placebo (SYNERGY-NASH phase 2 RCT) - Sources for this benefit: , , - Goals: [Sleep](https://humanpeptides.fyi/objectives/sleep) ## What do researchers and users say about Tirzepatide? > "Improvements in all prespecified cardiometabolic measures were observed with tirzepatide." > > Jastreboff AM, et al., Tirzepatide Once Weekly for the Treatment of Obesity. Context: SURMOUNT-1, a 72-week phase 3 placebo-controlled trial in 2539 adults with obesity (N Engl J Med, 2022). > "FDA is aware of fraudulent compounded semaglutide and tirzepatide marketed in the U.S. that contain false information on the product label." > > US Food and Drug Administration, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Context: FDA safety page on unapproved and counterfeit GLP-1 products (content current as of October 2026). > "My food noise and cravings are highest around day 4 and then actually drop again. Meanwhile nausea seems to creep up later in the week." > > Anonymous user, r/TirzepatideRX, My food noise is highest on day 4… not day 7. Anyone else?. Context: Unverified self-report on appetite and nausea across the weekly cycle; other users described different patterns. ## What side effects of Tirzepatide are reported? - Boxed warning: thyroid C-cell tumors in rodents; contraindicated with MTC/MEN2 history; also pancreatitis, gallbladder disease, hypoglycemia with insulin/sulfonylureas, kidney injury from dehydration, GI events (FDA label) Sources: - Nausea, constipation, diarrhea, vomiting, fatigue most common, especially during escalation (anecdotal/Reddit) Sources: - Pulmonary aspiration (inhaling stomach contents) has been reported in people on GLP-1-type drugs during general anesthesia or deep sedation. (FDA label) Sources: - Serious allergic reactions, including anaphylaxis and angioedema, have been reported after approval. (FDA label) Sources: - Hair loss, linked to weight reduction and reported more often in women than men. (FDA label) Sources: - Label warns of diabetic retinopathy complications in people with type 2 diabetes. (FDA label) Sources: - Slowed stomach emptying may reduce absorption of oral medicines, including oral hormonal contraceptives, and it may cause fetal harm. (FDA label) Sources: - Burping (eructation) and acid reflux (GERD) are among the most common reactions. (FDA label) Sources: - Counterfeit or falsely labeled compounded tirzepatide has been sold in the US, with one reported injection-site reaction from such a product. (regulator statement) Sources: ## What do peptide guides say about Tirzepatide? - **Dr. Axe:** Dr. Axe notes tirzepatide is one of four research-focused peptides on its list with FDA approval, for labeled weight and blood sugar uses, and that compounded copies are not the approved product. - **PepEdHub:** PepEdHub explains that activating both GIP and GLP-1 receptors improves insulin sensitivity, lowers glucagon, slows stomach emptying and dampens appetite through the brain. - **Seek Peptides:** Seek Peptides positions tirzepatide as a top option for people seeking maximum weight loss and for those with diabetes or prediabetes, describing its blood sugar control as stronger than semaglutide's. - **PubMed:** In SURMOUNT-1, about half of people on the two higher doses lost 20% or more of their body weight, compared with 3% on placebo. ## What does the research say, system by system? ### Body & tissues - Liver: resolves steatohepatitis (phase 2 RCT) Sources: - Upper airway/sleep apnea improvement largely tied to weight loss Sources: - Concerns raised about bone/muscle loss (osteosarcopenia) (commentary) Sources: ### Hormones & physiology - Dual incretin agonist: enhances glucose-dependent insulin secretion, lowers glucagon, slows gastric emptying, reduces appetite (FDA label) Sources: ### Brain, mood & sleep - Reduces 'food noise' (intrusive food thoughts), often early in treatment; can return late in the weekly cycle (anecdotal Reddit) Sources: , - FDA-approved for OSA, improving sleep-disordered breathing Sources: ### Weight & metabolism - ~21% weight loss at highest dose (phase 3) Sources: - Fat mass -33.9% vs -8.2% placebo; ~74% of weight lost was fat (DXA substudy) Sources: ### Muscle - Lean mass fell 10.9% vs 2.6% placebo; ~26% of weight lost was lean mass, similar proportion to diet-induced loss (DXA substudy) Sources: , ### Also notable - Practitioner week-by-week expectations: appetite drop, GI effects during dose escalation (clinic blog) Sources: ## How strong is the evidence for Tirzepatide? **Approved (specific use)** (5 of 5). FDA-approved, strong human phase 3 RCT data _Approved by the FDA (or a major regulator) for at least one specific use. Approval covers that use only, not the other benefits listed._ ## Street names and stacks - Street names: [Tirz](https://humanpeptides.fyi/street-names#nick-tirz) ## Questions about Tirzepatide ### What is Tirzepatide? Once-weekly injectable dual GIP/GLP-1 receptor agonist. ### Is Tirzepatide FDA-approved? Tirzepatide was first approved in the US in 2022, and Zepbound is FDA-approved, with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or with overweight and a weight-related condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity. ### What is Tirzepatide researched for? The sources cited on this page most often discuss three outcomes: Major weight loss; Blood sugar and heart risk; Less sleep apnea. Each line above shows what the source reports and how strong that evidence is. ### What side effects of Tirzepatide are reported? Reported in the cited sources: Boxed warning: thyroid C-cell tumors in rodents; contraindicated with MTC/MEN2 history; also pancreatitis, gallbladder disease, hypoglycemia with insulin/sulfonylureas, kidney injury from dehydration, GI events; Nausea, constipation, diarrhea, vomiting, fatigue most common, especially during escalation; Pulmonary aspiration (inhaling stomach contents) has been reported in people on GLP-1-type drugs during general anesthesia or deep sedation. The list is not complete, and few listed risks does not mean a compound is safe. ### How strong is the evidence for Tirzepatide? Evidence label: Approved (specific use). FDA-approved, strong human phase 3 RCT data. ### What else is Tirzepatide called? Names used for it include Mounjaro, Zepbound, LY3298176, twincretin, tirz, Tirz. ### Does humanpeptides.fyi recommend Tirzepatide? No. humanpeptides.fyi makes no claims and no recommendations of its own. It summarizes and links to what others have published and posted. Nothing here is medical advice; talk to a licensed clinician. --- Family: [Weight & Metabolic](https://humanpeptides.fyi/peptides?cat=metabolic). HTML version: . Disclaimer: